Lajos Pusztai, M.D, D.Phil.

A limitation of modern breast cancer adjuvant trials is that there are often not enough events in the experimental arm to demonstrate an effect, so we don’t know if the new drug actually works. The authors propose a method to make adjuvant clinical trials more effective by including in the trial only patients for whom current therapies do not work well — only if their risk for cancer recurrence with current best therapies is higher than a prespecified risk. (